Equities research analysts at Lazard Capital initiated coverage on shares of AVI BioPharma (NASDAQ: AVII) in a research note issued to investors on Thursday. They set a “buy” rating and a $5.00 price target on the stock.
Lazard Capital Markets is full service broker-dealer. Lazard’s Capital research covers the following Healthcare (BioPharma) companies:
- Aegerion
- NeurogesX
- Alkermes
- Novavax
- Amarin Corporation PLC
- NuPathe
- Amicus Therapeutics
- Orexigen Therapeutics
- Amylin Pharmaceuticals
- Pharmasset
- Arena Pharmaceuticals
- Raptor Pharmaceutical Corp.
- AVI BioPharma
- Savient Pharmaceuticals
- Cephalon
- Shire
- Endo Pharmaceuticals
- Transcept Pharmaceuticals
- Eurand
- Valeant Pharmaceuticals
- Forest Laboratories
- Ventrus Biosciences
- Genzyme Corp
- Vivus
- Human Genome Sciences
- Warner Chilcott
- Jazz Pharmaceuticals
- Xenoport
- MAP Pharmaceuticals
AVI Biopharma, Inc.
3450 Monte Villa Parkway
Suite 101
Bothell, WA 98021
Tel: 425-354-5038
AVI BioPharma focuses on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. By leveraging our highly differentiated RNA-based technology platform, company has built a pipeline of potentially transformative therapeutic agents, including a clinical stage Duchenne muscular dystrophy candidate and anti-infective candidates for influenza and hemorrhagic fever viruses.